| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival in multiple myeloma and the impact of novel therapies.
|
Blood
|
2007
|
12.70
|
|
2
|
Review of 1027 patients with newly diagnosed multiple myeloma.
|
Mayo Clin Proc
|
2003
|
9.96
|
|
3
|
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.
|
Blood
|
2005
|
5.82
|
|
4
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
5
|
POEMS syndrome: definitions and long-term outcome.
|
Blood
|
2002
|
4.35
|
|
6
|
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
|
J Clin Oncol
|
2004
|
3.43
|
|
7
|
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
|
J Clin Oncol
|
2012
|
3.35
|
|
8
|
Genomic abnormalities in monoclonal gammopathy of undetermined significance.
|
Blood
|
2002
|
3.34
|
|
9
|
Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis.
|
JACC Cardiovasc Imaging
|
2010
|
3.03
|
|
10
|
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
|
Blood
|
2004
|
2.97
|
|
11
|
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
|
Mayo Clin Proc
|
2006
|
2.88
|
|
12
|
Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma.
|
Blood
|
2007
|
2.87
|
|
13
|
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.
|
Mayo Clin Proc
|
2009
|
2.86
|
|
14
|
Amyloidosis: pathogenesis and new therapeutic options.
|
J Clin Oncol
|
2011
|
2.82
|
|
15
|
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
|
J Clin Oncol
|
2002
|
2.63
|
|
16
|
Clinical course of patients with relapsed multiple myeloma.
|
Mayo Clin Proc
|
2004
|
2.62
|
|
17
|
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.
|
Mayo Clin Proc
|
2013
|
2.59
|
|
18
|
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement.
|
Mayo Clin Proc
|
2007
|
2.55
|
|
19
|
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
|
J Clin Oncol
|
2009
|
2.50
|
|
20
|
Current therapy for multiple myeloma.
|
Mayo Clin Proc
|
2002
|
2.47
|
|
21
|
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.
|
Blood
|
2011
|
2.45
|
|
22
|
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma.
|
Mayo Clin Proc
|
2007
|
2.34
|
|
23
|
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma.
|
Blood
|
2003
|
2.12
|
|
24
|
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients.
|
Blood
|
2009
|
2.12
|
|
25
|
Eliminating the complete response penalty from myeloma response assessment.
|
Blood
|
2008
|
2.11
|
|
26
|
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
|
Blood
|
2006
|
2.06
|
|
27
|
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma.
|
J Clin Oncol
|
2013
|
2.01
|
|
28
|
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
|
Blood
|
2004
|
2.01
|
|
29
|
Immunoglobulin free light chains and solitary plasmacytoma of bone.
|
Blood
|
2006
|
1.98
|
|
30
|
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component.
|
Mayo Clin Proc
|
2009
|
1.96
|
|
31
|
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
|
Blood
|
2006
|
1.94
|
|
32
|
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.
|
Blood
|
2012
|
1.91
|
|
33
|
Waldenström macroglobulinemia.
|
Blood
|
2007
|
1.90
|
|
34
|
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
|
J Clin Oncol
|
2008
|
1.89
|
|
35
|
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS.
|
Blood
|
2005
|
1.87
|
|
36
|
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.
|
J Clin Oncol
|
2012
|
1.87
|
|
37
|
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.
|
Blood
|
2009
|
1.86
|
|
38
|
Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients.
|
Medicine (Baltimore)
|
2003
|
1.84
|
|
39
|
The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
|
Kidney Int
|
2013
|
1.79
|
|
40
|
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
|
Mayo Clin Proc
|
2003
|
1.72
|
|
41
|
Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma.
|
Blood
|
2005
|
1.66
|
|
42
|
Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement.
|
Am J Cardiol
|
2005
|
1.65
|
|
43
|
Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.
|
Lancet
|
2003
|
1.64
|
|
44
|
Autologous stem cell transplantation for primary systemic amyloidosis.
|
Blood
|
2002
|
1.58
|
|
45
|
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
|
Clin Cancer Res
|
2002
|
1.57
|
|
46
|
Early reduction of serum-free light chains associates with renal recovery in myeloma kidney.
|
J Am Soc Nephrol
|
2011
|
1.57
|
|
47
|
Waldenström macroglobulinaemia.
|
Lancet Oncol
|
2003
|
1.55
|
|
48
|
Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
|
Am J Clin Pathol
|
2003
|
1.55
|
|
49
|
Long-term outcome of allogeneic stem cell transplantation in chronic lymphocytic leukemia: analysis after a minimum follow-up of 5 years.
|
Leuk Lymphoma
|
2008
|
1.53
|
|
50
|
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.
|
Mayo Clin Proc
|
2011
|
1.53
|
|
51
|
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia.
|
Blood
|
2006
|
1.51
|
|
52
|
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
|
Nephrol Dial Transplant
|
2011
|
1.51
|
|
53
|
Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement.
|
Am J Transplant
|
2005
|
1.51
|
|
54
|
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma.
|
Blood
|
2006
|
1.50
|
|
55
|
Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
|
Biol Blood Marrow Transplant
|
2006
|
1.49
|
|
56
|
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
|
Haematologica
|
2005
|
1.49
|
|
57
|
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.
|
Amyloid
|
2003
|
1.47
|
|
58
|
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome.
|
Blood
|
2011
|
1.46
|
|
59
|
Long-term outcome of renal transplantation in light-chain deposition disease.
|
Am J Kidney Dis
|
2004
|
1.46
|
|
60
|
Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature.
|
Blood
|
2004
|
1.45
|
|
61
|
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2006
|
1.44
|
|
62
|
What do I need to know about immunoglobulin light chain (AL) amyloidosis?
|
Blood Rev
|
2012
|
1.43
|
|
63
|
Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: Results from a matched pair analysis.
|
Am J Hematol
|
2008
|
1.39
|
|
64
|
Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).
|
Blood
|
2002
|
1.39
|
|
65
|
Autologous stem cell transplantation and IgM amyloidosis.
|
Leuk Lymphoma
|
2006
|
1.38
|
|
66
|
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie.
|
Mayo Clin Proc
|
2010
|
1.34
|
|
67
|
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
|
Mayo Clin Proc
|
2010
|
1.32
|
|
68
|
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance.
|
Cancer Genet Cytogenet
|
2006
|
1.27
|
|
69
|
Current trends in diagnosis and management of cardiac amyloidosis.
|
Curr Probl Cardiol
|
2013
|
1.26
|
|
70
|
Treatment of Castleman's disease.
|
Curr Treat Options Oncol
|
2005
|
1.26
|
|
71
|
Early versus delayed autologous transplantation after immunomodulatory agents-based induction therapy in patients with newly diagnosed multiple myeloma.
|
Cancer
|
2011
|
1.20
|
|
72
|
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome.
|
Eur J Haematol
|
2008
|
1.19
|
|
73
|
Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies.
|
Am J Kidney Dis
|
2012
|
1.19
|
|
74
|
High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.
|
Blood
|
2011
|
1.19
|
|
75
|
Cold agglutinin disease.
|
Blood
|
2013
|
1.18
|
|
76
|
Changes in serum-free light chain rather than intact monoclonal immunoglobulin levels predicts outcome following therapy in primary amyloidosis.
|
Am J Hematol
|
2011
|
1.17
|
|
77
|
Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study.
|
Br J Haematol
|
2008
|
1.17
|
|
78
|
Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis.
|
Am J Med
|
2005
|
1.15
|
|
79
|
Immunoglobulin light chain amyloidosis.
|
Expert Rev Hematol
|
2013
|
1.15
|
|
80
|
Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.
|
Cancer
|
2004
|
1.14
|
|
81
|
Differentiation of constrictive pericarditis from restrictive cardiomyopathy using mitral annular velocity by tissue Doppler echocardiography.
|
Am J Cardiol
|
2004
|
1.14
|
|
82
|
Primary localized amyloidosis of the bladder: experience with dimethyl sulfoxide therapy.
|
J Urol
|
2002
|
1.14
|
|
83
|
Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
|
Br J Haematol
|
2012
|
1.14
|
|
84
|
The classification and typing of amyloid deposits.
|
Am J Clin Pathol
|
2004
|
1.12
|
|
85
|
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
|
Am J Hematol
|
2011
|
1.11
|
|
86
|
Clinical implication of centrosome amplification in plasma cell neoplasm.
|
Blood
|
2005
|
1.11
|
|
87
|
Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.
|
Br J Haematol
|
2006
|
1.11
|
|
88
|
Treatment of POEMS syndrome.
|
Curr Treat Options Oncol
|
2004
|
1.11
|
|
89
|
Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
|
Nephrol Dial Transplant
|
2008
|
1.10
|
|
90
|
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
|
Am J Hematol
|
2010
|
1.10
|
|
91
|
Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.
|
Circulation
|
2007
|
1.10
|
|
92
|
Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
|
Br J Haematol
|
2008
|
1.09
|
|
93
|
Smoldering multiple myeloma requiring treatment: time for a new definition?
|
Blood
|
2013
|
1.09
|
|
94
|
Cyclophosphamide mobilization does not improve outcome in patients receiving stem cell transplantation for multiple myeloma.
|
Clin Lymphoma Myeloma
|
2006
|
1.09
|
|
95
|
Relationship between depth of response and outcome in multiple myeloma.
|
J Clin Oncol
|
2007
|
1.09
|
|
96
|
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
|
Blood
|
2012
|
1.08
|
|
97
|
Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.
|
Blood
|
2010
|
1.08
|
|
98
|
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
|
Am J Hematol
|
2010
|
1.08
|
|
99
|
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system.
|
Blood
|
2005
|
1.08
|
|
100
|
The importance of bone marrow examination in determining complete response to therapy in patients with multiple myeloma.
|
Blood
|
2009
|
1.07
|
|
101
|
Proteomic analysis of waldenstrom macroglobulinemia.
|
Cancer Res
|
2007
|
1.07
|
|
102
|
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1.
|
Blood
|
2011
|
1.06
|
|
103
|
Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance.
|
J Clin Oncol
|
2005
|
1.05
|
|
104
|
Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.
|
Haematologica
|
2006
|
1.05
|
|
105
|
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma.
|
Blood
|
2004
|
1.05
|
|
106
|
Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
|
Clin Cancer Res
|
2007
|
1.04
|
|
107
|
Prognostic value of angiogenesis in solitary bone plasmacytoma.
|
Blood
|
2002
|
1.04
|
|
108
|
Bleeding complications after transcutaneous kidney biopsy in patients with systemic amyloidosis: single-center experience in 101 patients.
|
Am J Kidney Dis
|
2008
|
1.03
|
|
109
|
Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.
|
J Heart Lung Transplant
|
2008
|
1.03
|
|
110
|
Posttransplantation thrombotic thrombocytopenic purpura: a single-center experience and a contemporary review.
|
Mayo Clin Proc
|
2003
|
1.03
|
|
111
|
Outcomes of patients with POEMS syndrome treated initially with radiation.
|
Blood
|
2013
|
1.02
|
|
112
|
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis.
|
Blood
|
2002
|
1.02
|
|
113
|
Trends and outcomes of modern staging of solitary plasmacytoma of bone.
|
Am J Hematol
|
2012
|
1.01
|
|
114
|
Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
|
J Clin Oncol
|
2013
|
0.99
|
|
115
|
Fever of unknown origin caused by multiple myeloma: a report of 9 cases.
|
Arch Intern Med
|
2002
|
0.98
|
|
116
|
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia.
|
Blood
|
2012
|
0.98
|
|
117
|
Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.
|
Cancer
|
2012
|
0.97
|
|
118
|
Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
|
Am J Kidney Dis
|
2005
|
0.97
|
|
119
|
Advances in the treatment of amyloidosis.
|
N Engl J Med
|
2007
|
0.96
|
|
120
|
Cold agglutinin disease.
|
Haematologica
|
2006
|
0.96
|
|
121
|
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature.
|
Ann Hematol
|
2010
|
0.96
|
|
122
|
Cost-effectiveness analysis of a risk-adapted algorithm of plerixafor use for autologous peripheral blood stem cell mobilization.
|
Biol Blood Marrow Transplant
|
2012
|
0.95
|
|
123
|
Pitfalls in the diagnosis of primary amyloidosis.
|
Clin Lymphoma Myeloma Leuk
|
2010
|
0.95
|
|
124
|
Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.
|
Mayo Clin Proc
|
2010
|
0.95
|
|
125
|
Amyloidosis.
|
Adv Clin Chem
|
2009
|
0.95
|
|
126
|
Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003.
|
Blood
|
2008
|
0.94
|
|
127
|
Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
|
Semin Oncol
|
2003
|
0.94
|
|
128
|
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
|
Br J Haematol
|
2011
|
0.94
|
|
129
|
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
|
Leuk Lymphoma
|
2008
|
0.94
|
|
130
|
Renal apolipoprotein A-I amyloidosis associated with a novel mutant Leu64Pro.
|
Am J Kidney Dis
|
2004
|
0.94
|
|
131
|
Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
|
Nephrol Dial Transplant
|
2011
|
0.94
|
|
132
|
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis.
|
Clin Cancer Res
|
2005
|
0.94
|
|
133
|
Quantification of clonal circulating plasma cells in relapsed multiple myeloma.
|
Br J Haematol
|
2014
|
0.94
|
|
134
|
Multicentre versus single centre approach to rare diseases: the model of systemic light chain amyloidosis.
|
Amyloid
|
2005
|
0.93
|
|
135
|
Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis.
|
Haematologica
|
2009
|
0.93
|
|
136
|
Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis.
|
Circulation
|
2009
|
0.93
|
|
137
|
Treatment options for POEMS syndrome.
|
Expert Opin Pharmacother
|
2005
|
0.93
|
|
138
|
Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival.
|
Am J Hematol
|
2009
|
0.92
|
|
139
|
Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
|
Acta Haematol
|
2016
|
0.92
|
|
140
|
Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1.
|
J Interferon Cytokine Res
|
2006
|
0.91
|
|
141
|
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
|
N Engl J Med
|
2008
|
0.90
|
|
142
|
Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
|
Clin J Am Soc Nephrol
|
2007
|
0.90
|
|
143
|
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
|
Blood
|
2011
|
0.90
|
|
144
|
Acute weight gain and diastolic dysfunction as a potent risk complex for post stem cell transplant atrial fibrillation.
|
Am J Hematol
|
2009
|
0.90
|
|
145
|
A phase II trial of imatinib in patients with refractory/relapsed myeloma.
|
Leuk Lymphoma
|
2006
|
0.89
|
|
146
|
Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression.
|
Cancer Genet Cytogenet
|
2002
|
0.89
|
|
147
|
Natural history of thromboembolism in AL amyloidosis.
|
Amyloid
|
2006
|
0.88
|
|
148
|
Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients.
|
Blood
|
2005
|
0.88
|
|
149
|
Diagnosing primary amyloidosis.
|
Mayo Clin Proc
|
2002
|
0.88
|
|
150
|
Thermal stability threshold for amyloid formation in light chain amyloidosis.
|
Int J Mol Sci
|
2013
|
0.88
|
|
151
|
Acute renal insufficiency after high-dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation.
|
Am J Kidney Dis
|
2005
|
0.87
|
|
152
|
Serum immunoglobulin free light chain measurements and heavy chain isotype usage provide insight into disease biology in patients with POEMS syndrome.
|
Am J Hematol
|
2010
|
0.87
|
|
153
|
Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis.
|
Cardiovasc Pathol
|
2007
|
0.87
|
|
154
|
Hereditary ATTR amyloidosis: a single-institution experience with 266 patients.
|
Amyloid
|
2015
|
0.86
|
|
155
|
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
|
Blood
|
2012
|
0.86
|
|
156
|
Natural history and therapy of 66 patients with mixed cryoglobulinemia.
|
Am J Hematol
|
2006
|
0.86
|
|
157
|
Lenalidomide plus dexamethasone vs. lenalidomide plus melphalan and prednisone: a retrospective study in newly diagnosed elderly myeloma.
|
Eur J Haematol
|
2010
|
0.86
|
|
158
|
Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.
|
Blood
|
2004
|
0.85
|
|
159
|
Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma.
|
Am J Hematol
|
2010
|
0.85
|
|
160
|
A detailed evaluation of the current renal response criteria in AL amyloidosis: is it time for a revision?
|
Haematologica
|
2013
|
0.85
|
|
161
|
Serum M-spike and transplant outcome in patients with multiple myeloma.
|
Cancer Sci
|
2007
|
0.84
|
|
162
|
Hematopoietic recovery kinetics predicts for poor CD34+ cell mobilization after cyclophosphamide chemotherapy in multiple myeloma.
|
Am J Hematol
|
2011
|
0.83
|
|
163
|
Serum uric acid: novel prognostic factor in primary systemic amyloidosis.
|
Mayo Clin Proc
|
2008
|
0.83
|
|
164
|
Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasias.
|
Am J Hematol
|
2014
|
0.83
|
|
165
|
Successful treatment of scleromyxedema with autologous peripheral blood stem cell transplantation.
|
Arch Dermatol
|
2005
|
0.83
|
|
166
|
Managing myeloma kidney.
|
Ann Intern Med
|
2005
|
0.82
|
|
167
|
Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.
|
J Clin Immunol
|
2006
|
0.82
|
|
168
|
Response to rituximab in patients with type II cryoglobulinemia.
|
Clin Lymphoma Myeloma
|
2006
|
0.82
|
|
169
|
Amyloidosis and POEMS syndrome.
|
Expert Opin Pharmacother
|
2010
|
0.81
|
|
170
|
Quantitative analysis of clonal bone marrow CD19+ B cells: use of B cell lineage trees to delineate their role in the pathogenesis of light chain amyloidosis.
|
Clin Immunol
|
2006
|
0.81
|
|
171
|
Implications of continued response after autologous stem cell transplantation for multiple myeloma.
|
Blood
|
2013
|
0.81
|
|
172
|
Cost-effectiveness analysis of early vs. late autologous stem cell transplantation in multiple myeloma.
|
Clin Transplant
|
2014
|
0.80
|
|
173
|
Left ventricular device implantation for advanced cardiac amyloidosis.
|
J Heart Lung Transplant
|
2013
|
0.80
|
|
174
|
Does stem cell transplantation have a role in the management of multiple myeloma, 2009?
|
Expert Opin Pharmacother
|
2009
|
0.79
|
|
175
|
In vivo and in silico studies on single versus multiple transplants for multiple myeloma.
|
Cancer Sci
|
2007
|
0.79
|
|
176
|
Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator.
|
Leuk Lymphoma
|
2002
|
0.79
|
|
177
|
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myeloma.
|
Am J Hematol
|
2010
|
0.79
|
|
178
|
The effect of absolute lymphocyte count recovery kinetics on survival after autologous stem cell transplantation for non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2005
|
0.79
|
|
179
|
Globular amyloid deposits isolated to the small bowel: a rare association with AL amyloidosis.
|
Am J Surg Pathol
|
2007
|
0.78
|
|
180
|
Evaluation of pretransplant factors predicting cardiac dysfunction following high-dose melphalan conditioning and autologous peripheral blood stem cell transplantation.
|
Eur J Haematol
|
2012
|
0.78
|
|
181
|
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
|
Expert Rev Anticancer Ther
|
2015
|
0.78
|
|
182
|
Recent advances in the diagnosis and management of cardiac amyloidosis.
|
Future Cardiol
|
2014
|
0.78
|
|
183
|
Bone marrow angiogenesis in multiple myeloma: effect of therapy.
|
Br J Haematol
|
2002
|
0.78
|
|
184
|
Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response.
|
Am J Hematol
|
2004
|
0.78
|
|
185
|
Domino liver transplantation as a cause of acquired familial amyloid polyneuropathy.
|
Amyloid
|
2014
|
0.78
|
|
186
|
Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al).
|
J Am Soc Echocardiogr
|
2011
|
0.78
|
|
187
|
Analysis of somatic hypermutation and antigenic selection in the clonal B cell in immunoglobulin light chain amyloidosis (AL).
|
J Clin Immunol
|
2004
|
0.77
|
|
188
|
Primary systemic amyloidosis presenting with asymmetric multiple mononeuropathies.
|
J Clin Oncol
|
2010
|
0.77
|
|
189
|
Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis.
|
Am J Hematol
|
2011
|
0.77
|
|
190
|
Current treatment options for Waldenström macroglobulinemia.
|
Clin Lymphoma Myeloma
|
2008
|
0.77
|
|
191
|
Multiple myeloma after kidney transplantation.
|
Clin Transplant
|
2014
|
0.77
|
|
192
|
Risk adapted therapy for multiple myeloma: back to basics.
|
Leuk Lymphoma
|
2014
|
0.77
|
|
193
|
Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
0.77
|
|
194
|
Autologous attack on amyloidosis.
|
Mayo Clin Proc
|
2006
|
0.77
|
|
195
|
Refractory atypical hemolytic uremic syndrome with monoclonal gammopathy responsive to bortezomib-based therapy.
|
Clin Nephrol
|
2015
|
0.76
|
|
196
|
Genotype, echocardiography, and survival in familial transthyretin amyloidosis.
|
Amyloid
|
2013
|
0.76
|
|
197
|
Thrombotic microangiopathy during peripheral blood stem cell mobilization.
|
J Clin Apher
|
2009
|
0.76
|
|
198
|
Localized AL amyloidosis of the colon: an unrecognized entity.
|
Amyloid
|
2003
|
0.76
|
|
199
|
The current landscape of multiple myeloma treatment.
|
Leuk Res
|
2008
|
0.76
|
|
200
|
Ibrutinib for the treatment of Waldenström macroglobulinemia.
|
Expert Rev Hematol
|
2015
|
0.76
|
|
201
|
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.
|
Am J Hematol
|
2015
|
0.76
|
|
202
|
Improving strategies for the diagnosis of cardiac amyloidosis.
|
Expert Rev Cardiovasc Ther
|
2015
|
0.75
|
|
203
|
Factors associated with favorable outcome after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
204
|
High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis.
|
Biol Blood Marrow Transplant
|
2009
|
0.75
|
|
205
|
A novel report of cig-FISH and cytogenetics in POEMS syndrome.
|
Am J Hematol
|
2008
|
0.75
|
|
206
|
The spectrum of monoclonal gammopathies affecting the kidney.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
207
|
Waldenström macroglobulinaemia: the key questions.
|
Br J Haematol
|
2013
|
0.75
|
|
208
|
The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
209
|
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma.
|
Br J Haematol
|
2009
|
0.75
|
|
210
|
Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
|
Mayo Clin Proc
|
2010
|
0.75
|
|
211
|
A reappraisal of immunoglobulin variable gene primers and its impact on assessing clonal relationships between PB B cells and BM plasma cells in AL amyloidosis.
|
J Clin Immunol
|
2011
|
0.75
|
|
212
|
Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myeloma.
|
Cancer
|
2010
|
0.75
|
|
213
|
Bortezomib-based combination regimens in myeloma: more is not necessarily better.
|
Leuk Lymphoma
|
2014
|
0.75
|
|
214
|
Long-term disease control in patients with newly diagnosed multiple myeloma after suspension of lenalidomide therapy.
|
Am J Hematol
|
2014
|
0.75
|
|
215
|
Activity of bortezomib administered once every 3 weeks for treatment of relapsed multiple myeloma.
|
Leuk Lymphoma
|
2009
|
0.75
|
|
216
|
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
217
|
An unusual neurological complication of light chain amyloidosis.
|
Br J Haematol
|
2009
|
0.75
|
|
218
|
Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges.
|
Am J Manag Care
|
2017
|
0.75
|
|
219
|
Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
|
Clin Adv Hematol Oncol
|
2012
|
0.75
|
|
220
|
Myeloma and the newly diagnosed patient: a focus on treatment and management.
|
Semin Oncol
|
2002
|
0.75
|
|
221
|
Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency.
|
Blood Coagul Fibrinolysis
|
2016
|
0.75
|
|
222
|
Death during coronary angiography in a woman with cardiac amyloidosis.
|
Amyloid
|
2006
|
0.75
|
|
223
|
Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
|
Eur J Haematol
|
2014
|
0.75
|
|
224
|
OCULAR MANIFESTATIONS OF SYSTEMIC AMYLOIDOSIS.
|
Retina
|
2017
|
0.75
|